Farzana Perwad, MD
My research focus is to understand the molecular mechanisms of regulation of phosphorus and vitamin D metabolism in the setting of chronic kidney disease.
Education
2005 - Pediatric Nephrology, University of California San Francisco
MD, 2001 - Pediatrics, Nicklaus Children's Hospital
MBBS, 1996 - Medicine, Kasturba Medical College
Websites
Publications
- Genetic Variants Associated with Mineral Metabolism Traits in Chronic Kidney Disease.
- Adverse Consequences of Chronic Kidney Disease on Bone Health in Children.
- Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
- Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling.
- Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
- Chapter 7 The experimental detection of FGF23 responsiveness in target organs.
- Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial.
- Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
- Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.
- OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial.
- a-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases.
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
- Fibroblast growth factor 23 and phosphate homeostasis.
- Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
- Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
- Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.
- Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
- Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury.
- Vitamin D and kidney disease.
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
- Monogenic Causes of Proteinuria in Children.
- Autoimmune hyperphosphatemic tumoral calcinosis.
- Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
- Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
- Phosphate Homeostasis and Metabolic Bone Disease.
- FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues.
- Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
- Chapter 25 Rickets Due to Hereditary Abnormalities of Vitamin D Synthesis or Action.
- Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
- Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.
- Calcium and Phosphorus.
- Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.
- Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency.
- Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.